Table 1:

Clinico-pathological features of RAS / RAF mutated RMS

Case #	Age (yrs)	Sex	Site	RAS / RAF mutation	Risk Group	FU duration (months)	FU status	Treatment
1¥	1	F	buttock	NRAS exon3 p.Q61K (c.181 C>A)	High	15	DOD	S+C
2	2	M	Para-testicular	NRAS exon3 p.Q61K (c.181C>A)	Low	48	NED	S+C
3¤	2	M	soft palate	NRAS exon3 p.Q61K (c.181C>A)	Low	15	AWD	S+C
4§	2	F	thigh	NRAS exon3 p.Q61K (c.181C>A)	NA	19	NED	C+R+S
5¤	3	M	pelvis	NRAS exon3 p.Q61H (c.183A>T)	Int	16	NED	C+R+S
6	3	F	vagina	NRAS exon3 p.Q61K (c.181C>A)	Low	17	NED	C+R+S
7	5	M	jaw	NRAS exon2 p.G13V (c.38G>T)	Int	22	NED	S+C
8	7	M	Para-testicular	NRAS exon3 p.Q61K (c.181C>A)	Low	36	NED	S+C
9¤	9	M	infratemporal fossa	NRAS exon3 p.Q61L (c.182A>T)	Int	55	NED	C+R+S
10	10	M	abdomen	NRAS exon3 p.Q61R (c.182A>G)	Int	3	DOD	C+S
11§	19	F	vagina	NRAS exon3 p.Q61K (c.181C>A)	Int	34	DOD	C+R+S
12	34	F	cervix	NRAS exon3 p.Q61R (c.182A>G)	Int	2	AWD	C
13¤	62	M	calf	NRAS exon3 p.Q61K (c.181C>A)	Int	60	NED	C+R+S
14	70	M	axilla	NRAS exon3 p.Q61L (c.182A>T)	Int	35	NED	C+R+S
15	1	M	pelvis	KRAS exon 2 p.G12D (c.35G>A)	High	12	DOD	C+R+S
16¤	1	F	vagina	KRAS exon2 p.G12D (c.35G>A)	Low	28	AWD	C+R+S
17	2	M	pelvis	KRAS exon 2 p.G12D (c.35G>A)	Int	31	NED	C+R+S
18¥	23	M	Para-testicular	KRAS exon4 p.K117T (c.350A>C)	High	52	NED	C+R+S
19	44	F	uterus	KRAS exon2 p.G12A (c.35G>C)	Low	19	NED	S+C
20¥	62	F	endometrium	KRAS exon2 p.G12D (c.35G>A)	NA	4	DOD	S+C
21¤	3	F	orbit	HRAS exon3 p.Q61K (c.181C>A)	Low	39	NED	C+R+S
22¥	20	M	Para-testicular	HRAS exon2 p.G12V (c.35G>T)	Low	54	DOD	C+R+S
23	22	F	buccal	HRAS exon 3 p.Q61L	Low	124	NED	C+R+S
24¤	32	M	pterygoid fossa	HRAS exon 2 p.G13R	Int	64	DOD	C+R+S
25	50	M	thigh	HRAS exon3 p.T50M (c.149C>T)	Int	5	AWD	S+C
26¥	4	M	abdomen	BRAF exon15 p.V600E (c.1799T>A)	High	8	AWD	C

F-female, M-male, int-intermediate, NA-not available, DOD-died of disease, AWD-alive with disease, NED-no evidence of disease, C-chemotherapy, S-surgery, R-radiation therapy

^¥-Distant recurrence

^¤-Local recurrence

^§-Local and distant recurrence